ライフサイエンスコーパス: disease

1 ve been used to study heart damage in Chagas disease.

2 YMP) and develop frequent bouts of recurrent disease.

3 e important contributors to human health and disease.

4 n few studies on antibiotic use and allergic disease.

5 roke, heart failure, and peripheral arterial disease.

6 rst-line/initial chemotherapy for metastatic disease.

7 opulation is referred to as minimal residual disease.

8 ar damaged neurons, or pathologically during disease.

9 sts as potential therapeutics for this fatal disease.

10 gene is related to the gene's causal role in disease.

11 he tissues and cells that pertain to a given disease.

12 al strains and functions associated with the disease.

13 questionnaire covered various aspects of the disease.

14 y evaluations to exclude secondary causes of disease.

15 of p19/Arf is detected, recapitulating human disease.

16 disorders and may play a role in triggering disease.

17 laxis in neonates at high risk of severe RSV disease.

18 s that may ultimately prevent myopia-related disease.

19 i-inflammatory approach in diabetic vascular disease.

20 s to inhibit or prevent metastatic spread of disease.

21 ria) with the incidence of peripheral artery disease.

22 th acute myeloid leukemia (AML) die of their disease.

23 in kinases play a pivotal role in health and disease.

24 nor response, stable disease, or progressive disease.

25 Clinical Trials in Chronic Graft-Versus-Host Disease.

26 lar risk factors, stroke, and chronic kidney disease.

27 BTBR Lep(ob) mice exhibited diabetic kidney disease.

28 tal lung ventilation reflecting small-airway disease.

29 h as allergy, asthma, and inflammatory bowel disease.

30 is in more than half of patients with active disease.

31 and methods of determining minimal residual disease.

32 ealth consequences such as neurodegenerative disease.

33 p pruritus (itch) during the course of their disease.

34 and Helicobacter pylori infection as a model disease.

35 he full genetic architecture of rare complex diseases.

36 drug targets to treat APOL1-associated renal diseases.

37 ication, such as Alzheimer's and Parkinson's diseases.

38 ts contribute to propagation of inflammatory diseases.

39 d in cellular homeostasis and the associated diseases.

40 S1PR) agonism in the treatment of infectious diseases.

41 uence many aspects of metabolism and related diseases.

42 n of the role of mesentery fat in colorectal diseases.

43 ther investigation of PD-1 blockade in these diseases.

44 mune cells and their roles in immune-related diseases.

45 ead to increased vulnerability to infectious diseases.

46 ed to several interrelated neurodegenerative diseases.

47 rns associated with human inflammatory bowel diseases.

48 been linked to immunological and neoplastic diseases.

49 a therapeutic target for treating autoimmune diseases.

50 4%), EA2 (13%), SPG7 (10%) and mitochondrial disease (10%).

51 lonization, (2) cases of infant invasive GBS disease, (3) deaths, and (4) disabilities.

52 es during the development of allergic airway disease (AAD).

53 veness of screening and treatment for celiac disease, accuracy of screening tests in asymptomatic per

54 n is an important contributor to Alzheimer's disease (AD) pathogenesis, as underscored by the recent

55 the forebrain and degenerates in Alzheimer's disease (AD).

56 Alzheimer's disease (AD; n = 164) was identified with 70% sensitivit

57 antly increased for patients with metastatic disease (adjusted hazard ratio [AHR], 2.3; 95% CI, 1.0 t

58 is a prototypical B cell-mediated autoimmune disease affecting 20-50 people per 100,000.

59 5 is an expression biomarker for a number of diseases affecting striated muscle and may also be a sch

60 orectal liver metastases with liver-dominant disease after chemotherapy.

61 nd 48 (51.6%) were diagnosed with late-stage disease (AJCC stage III or IV).

62 yelitis optica spectrum disorders, Parkinson disease, Alzheimer disease, Huntington disease, and amyo

63 , 45 (48.4%) were diagnosed with early-stage disease (American Joint Committee on Cancer [AJCC] stage

64 (CNS), causing the adult-onset degenerative disease amyotrophic lateral sclerosis (ALS).

65 a powerful approach for studying its role in disease and aging.

66 l lead to new diagnostic tools for Alzheimer disease and better understanding of its neurobiology.

67 n independent risk factor for coronary heart disease and cardiovascular mortality.

68 ary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk), was used to assess expos

69 ividuals with atherosclerotic cardiovascular disease and healthy controls, identifying microbial stra

70 significantly higher rates of cardiovascular disease and hypotension.

71 p to elucidate the complex mechanisms of the disease and lead to the development of more effective in

72 s in colostrum and breast milk with allergic disease and lung function at ages 12 and 18 years.

73 bnormalities may not allow detection of mild disease and may lead to underestimation of severity.

74 anding hypoxia-mediated mechanisms in cancer disease and other biological processes, and discovery of

75 R imaging in differentiation between Graves' disease and painless thyroiditis.

76 Prion diseases, like Alzheimer's disease and Parkinson disease, are rapidly progressive n

77 omes included cumulative CVD (coronary heart disease and stroke) deaths prevented or postponed and li

78 role of B cells in controlling cCMV-related disease and the clinical value of this marker as a predi

79 greater understanding of the pathogenesis of disease and the realization of precision medicine.

80 terogeneity, AD is still considered a single disease and usually treated according to the "one-size-f

81 major cause of severe hand, foot, and mouth disease and viral encephalitis in children across the As

82 ely employed for diagnosing a broad array of diseases and disorders in clinical settings worldwide.

83 ential target for the treatment of metabolic diseases and has been extensively investigated and valid

84 c target for treating hypoxic-ischemic human diseases and organ transplantation.

85 tion in specific EBV genes relevant to these diseases and proposed EBV vaccines.

86 as a model to study aquatic enveloped virus diseases and their inhibition.

87 ious genetic disorders (e.g., the Huntington disease), and thus was used in genetic testing for scree

88 to normal development, adult homeostasis and disease, and also revealed novel mechanisms by which TGF

89 inson disease, Alzheimer disease, Huntington disease, and amyotrophic lateral sclerosis.

90 sis infection, diabetes, chronic respiratory disease, and blindness health programmes; provision of e

91 tervention for the treatment of Huntington's disease, and potentially for other neurodegenerative dis

92 Complete and partial response, stable disease, and progressive disease were defined according

93 s for patients with prevalent coronary heart disease, and we offer recommendations, when data are ava

94 ical processes used by A. baumannii to cause disease are not well defined, but recent research has in

95 to identify associations between lncRNAs and diseases are expensive and time-consuming.

96 fective drug treatments for many psychiatric diseases are lacking, and the emerging tools and approac

97 ases, like Alzheimer's disease and Parkinson disease, are rapidly progressive neurodegenerative disor

98 ranslation modification in neurodegenerative diseases as well as other pathological conditions.

99 taining proteins are aberrantly expressed in diseases, as best studied in cancers, where bromodomain

100 se patient outcome, monitor minimal residual disease, assess tumour resistance to therapeutic agents,

101 Psoriasis, a chronic inflammatory skin disease associated with increased susceptibility to athe

102 e two configurations, which may give rise to disease-associated repeat expansion.

103 s show tissue- and cell-type specificity and disease-associated variants are often enriched for CREs

104 ery, explore the phenotypic consequences for disease-associated variants, and test causal inference.

105 ecurrence included model for end-stage liver disease at LT >23, time to recurrence, >3 recurrent nodu

106 ent pathogenetic pathways, and benign breast disease (BBD) predicts future non-TNBC.

107 personalized in vivo models of genetic renal diseases bearing patient-specific mutations.

108 assessment of structural and residual heart disease before and after surgery, quantification of vent

109 There were no differences in allergic disease between LEAP groups.

110 he predictive ability with respect to severe disease beyond that of individual questionnaire items.

111 erapies are not guided by individual risk or disease biology.

112 otheses for disease mechanisms, identify new disease biomarkers, and reposition drugs for diseases wi

113 ts, and increased over 1 year in Parkinson's disease but not in controls at a single site.

114 tokine levels in patients with chronic liver disease, but comprehensive cytokine profiling data acros

115 with chlamydiae develop upper genital tract disease, but the reason(s) for this remains undefined.

116 ystem is a promising target for treatment of disease, but this remains to be realized due to rapid pr

117 avastatin reduced the risk of coronary heart disease by 27% (P=0.033) and major adverse cardiovascula

118 n miRNAs and their targetome in Chagas heart disease by integrating gene and microRNA expression prof

119 hood glaucomas have strong genetic bases and disease-causing mutations have been discovered in severa

120 ouse model of AxD that is heterozygous for a disease-causing point mutation (Gfap(R236H)(/+)) (and th

121 ngth in dogs is a unique example of multiple disease-causing retrocopies of the same parental gene in

122 tory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are complex ch

123 Pathogenesis of Crohn's disease (CD) involves immune and microbial dysregulation

124 e necessary interventions to rejuvenate aged/diseased cells and improve their regenerative capacities

125 cience University Layton Aging and Alzheimer Disease Center and Oregon Brain Bank.

126 Systemic sclerosis is an autoimmune disease characterized by T-cell infiltration in the skin

127 a breakdown of the DMN in many neurological diseases characterized by declined cognitive flexibility

128 During human immunodeficiency virus (HIV) disease, chronic immune activation leads to T-cell exhau

129 s 172 suffered from a chronic ischemic heart disease (CIHD), 126 of whom underwent challenges.

130 control) or with hypertensive chronic kidney disease (CKD).

131 substantia nigra was elevated in Parkinson's disease compared to controls across single- and multi-si

132 spects of Ca signaling under both normal and diseased conditions.

133 cities participating in the U.S. Centers for Disease Control and Prevention (CDC)'s Climate-Ready Sta

134 ion Patient Registry merged with Centers for Disease Control and Prevention respiratory virus surveil

135 Disease control has been proven in the metastatic and, t

136 aftment and leads to acceptable toxicity and disease control in the setting of high risk, heavily pre

137 mprove clinical management and public health disease control.

138 Chronic obstructive pulmonary disease (COPD) is regarded as a disease of accelerated l

139 = 15), and calcium pyrophosphate deposition disease (CPPD) (n = 15), from the Hamann-Todd collection

140 h the risk for and outcome of cardiovascular diseases (CVDs).

141 ng chronic shedding using commonly collected disease data is hampered by numerous challenges, includi

142 l trial phase and the risk of coronary heart disease death, cardiovascular death, and all-cause morta

143 perating within and across organs throughout disease development by integrating in vivo analysis of g

144 novel, and less invasive, opportunities for disease diagnosis.

145 myosarcoma (ARMS) is a devastating pediatric disease driven by expression of the oncogenic fusion gen

146 for HER1/2 and who did not have progressive disease during chemotherapy (four to eight cycles) were

147 sociations of two measures of chronic kidney disease (estimated glomerular filtration rate [eGFR] and

148 e traits are risk factors for cardiovascular disease even below the diabetic threshold, and their stu

149 th increase the prevalence of cardiovascular disease events.

150 Key eligibility criteria included measurable disease, failure of standard therapy, and Eastern Cooper

151 motherapy-induced regressions of established disease followed by lethal regrowth of more aggressive t

152 there are many gastrointestinal and hepatic diseases for which obesity is the direct cause (eg, nona

153 the strongest predictor of overall (OS) and disease free survival (DFS) (p = 0.00001; p = 0.01, resp

154 om nine cohorts of patients with Parkinson's disease from North America and Europe assessed between 1

155 ore analysis for the prediction of Alzheimer disease have given area under the curve (AUC) estimates

156 Treatment strategies for these diseases have often targeted downstream pathways to amel

157 iffuse pattern had more features of advanced disease, higher international staging system score, incr

158 f tissue has helped to reveal the origins of disease; however, cellular-scale resolution is not readi

159 trienes has been associated with periodontal diseases; however their relative contribution to the tis

160 trum disorders, Parkinson disease, Alzheimer disease, Huntington disease, and amyotrophic lateral scl

161 atosis polyposis (FAP) or inflammatory bowel disease (IBD).

162 Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcer

163 The pathogenic role of ischemic heart disease (IHD) in heart failure (HF) with reduced ejectio

164 n the timing of onset and progression of the disease in childhood is lacking.

165 uenza A viruses are able to infect and cause disease in mammals without prior adaptation and therefor

166 linked to differential susceptibility to the disease in many species.

167 tnam, which has experienced a high burden of disease in recent years.

168 anism Ceratonova shasta, which causes lethal disease in salmonids.

169 llected and analyzed in the study of complex diseases in quest of improving human health.

170 o cardiorespiratory abnormalities present in diseases in which the carotid bodies are hyperactive at

171 ved in the pathogenesis of inflammatory skin diseases including chronic urticaria which is associated

172 ritical in the pathology of many respiratory diseases, including cystic fibrosis.

173 alling is associated with a variety of human diseases, including metabolic disorders and cancer.

174 cines; and concomitant integration of fungal disease into training of the health workforce.

175 oach including greater integration of fungal diseases into existing HIV infection, tuberculosis infec

176 ffective in preventing invasive pneumococcal disease (IPD), but deaths due to IPD still occur.

177 Invasive pneumococcal diseases (IPDs) remain the leading cause of vaccine-prev

178 Inherited retinal disease is a common cause of visual impairment and repre

179 CS patients with obstructive coronary artery disease is associated with a high reclassification rate

180 ovascular disease risk is elevated and liver disease is common.

181 unclassified before the age of 10 years, the disease is complex, multifactorial, and lifelong, and af

182 e been gained into the pathogenesis of these diseases, it is not fully understood how distinct GJB2 m

183 gets for the treatment of estrogen-dependent diseases like endometriosis and breast cancer.

184 can be impaired in patients with common eye diseases like glaucoma and age-related macular degenerat

185 Prion diseases, like Alzheimer's disease and Parkinson disease

186 immune dysregulation, setting the stage for disease manifestations characteristic of M. gallisepticu

187 uggest the prevalence of pediatric and adult disease may be similar.

188 per L vs >/=10 x 10(9) platelets per L) and disease (MDS vs AML).

189 essential for improving our understanding of disease mechanisms contributing to risk and resilience.

190 ular data sets to develop new hypotheses for disease mechanisms, identify new disease biomarkers, and

191 with cirrhosis and Model for End-Stage Liver Disease (MELD) score within 3 months of initial liver CT

192 tine application of hPSC-derived lineages in disease modeling and regenerative medicine.

193 em cell biology to regenerative medicine and disease modeling.

194 This is partly due to the lack of disease models recapitulating the human pathology.

195 ed, including pharmacological treatments and disease models.

196 available drugs has shown clear evidence of disease-modifying activity, even if some patients treate

197 There are no disease-modifying therapies for either FTD or NCL, in pa

198 ase, which may be used in clinical trials of disease-modifying therapies.

199 sease progression and evaluating preclinical disease-modifying treatment response.

200 and strengthen the evidence for circulatory-disease mortality radiation risk at doses <0.5 Gy.

201 Purpose Minimal residual disease (MRD) and genetic abnormalities are important ri

202 Although often described as a childhood disease, newer population-based estimates suggest the pr

203 ve pulmonary disease (COPD) is regarded as a disease of accelerated lung aging.

204 Type 1 diabetes is typically considered a disease of children and young adults.

205 rculosis (TB) is an important and widespread disease of wildlife, livestock and humans world-wide, bu

206 hese animals display a significantly earlier disease onset and reduced overall survival, compared to

207 ) or clinically isolated syndrome (CIS) with disease onset before 18 years of age and duration of les

208 al data suggest a correlation between age at disease onset, response to sodium channel blockers and t

209 ognitive decline associated with Alzheimer's disease or schizophrenia.

210 e direct cause (eg, nonalcoholic fatty liver disease) or is a significant risk factor, such as reflux

211 se, partial response, minor response, stable disease, or progressive disease.

212 omes more and more routine during infectious disease outbreaks.

213 explored as therapeutic adjuvants to improve disease outcomes during intracellular bacterial infectio

214 tory disease (p = 0.014) and ischaemic heart disease (p = 0.003), possibly due to competing causes of

215 ve mortality dose trends for all circulatory disease (p = 0.014) and ischaemic heart disease (p = 0.0

216 anding of the epidemiology of cardiovascular diseases, particularly stroke.

217 mutations in genes such as GRN contribute to disease pathogenesis and neurodegeneration.

218 gments (encoded by HTT exon 1) underlies the disease pathology in mouse models and that the HTT exon

219 tions on the medical management of Parkinson disease (PD) during Ramadan.

220 vodopa-induced dyskinesia (LID) in Parkinson disease (PD) is an unmet need.

221 Parkinson's disease (PD) patients experience loss of normal motor fu

222 ve impairment (MCI), patients with Parkinson disease (PD), and young and older healthy volunteers.

223 a network effect that will benefit multiple disease programs.

224 d outcomes are consistent with slow rates of disease progression (median doubling time: 84 days, 95%

225 major determinant of subtype differences in disease progression among HIV-1 subtypes; furthermore, w

226 potential use for monitoring HD mouse model disease progression and evaluating preclinical disease-m

227 tion, measured by sj/beta-TREC ratio, in HIV disease progression by analyzing a large number of patie

228 Disease progression includes composite mortality, hospit

229 A liver disease progression Markov model, which used a lifetime

230 ths vs. 36 months; adjusted hazard ratio for disease progression or death, 0.65; P<0.001).

231 Hazard of disease progression or recurrence was significantly incr

232 psules (2.5 mg/day) for 28-day cycles, until disease progression or unacceptable toxicity.

233 of patients in 3 cohorts with different HIV disease progression phenotypes.

234 but nonzero, probability of transition from disease progression to recovery (median 16% per year, 95

235 ny BRAF-mutated melanoma patients experience disease progression with targeted BRAF inhibitors, we hy

236 435/1449 may contribute to the modulation of disease progression.

237 d as hallmarks that correlated with clinical disease progression.

238 rofile of individual cells in the context of disease progression.

239 BLAST for eligible patients with infectious diseases receiving nonpreferred therapy due to severity

240 ved placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1

241 in bound paclitaxel is effective in inducing disease regression in treatment-refractory breast cancer

242 on of 5-FU followed by GDC-0941 may suppress disease relapse after 5-FU-based gastric cancer chemothe

243 e prognostic significance of CNA presence in disease relapse in patients with AML.

244 nd methods, we also quantified the burden of disease related to high body-mass index (BMI), according

245 Risks of disease-related outcomes and 5-year recurrence-free, dis

246 Understanding and treating this disease remains a challenge, as seizures manifest throug

247 ined here offer researchers studying complex diseases renewed opportunities to discover new or repurp

248 he pathogenesis and the progression of prion diseases, representing a valid tool for distinguishing d

249 ciation with the treatment of the underlying disease, represents a valid approach that can improve th

250 Psoriasis is a chronic inflammatory disease resulting from dysregulated immune activation as

251 C infected people among whom cardiovascular disease risk is elevated and liver disease is common.

252 , and low Framingham 10-year coronary artery disease risk scores with an echocardiogram, exercise str

253 een circulating C15:0/C17:0 fatty acids with disease risk, therefore, their origin needs to be determ

254 ic etiology can be a prognostic indicator of disease severity and can influence treatment decisions.

255 m provides recommendations for assessment of disease severity, data collection, and endpoint definiti

256 e and make recommendations for assessment of disease severity, data collection, and updated endpoint

257 Many common diseases show wide phenotypic variation.

258 psis were associated with worse colon cancer disease-specific survival [(+)transfusion: hazard ratio

259 : HR 2.27, 95% CI 1.87-2.76], cardiovascular disease-specific survival [(+)transfusion: HR 1.18, 95%

260 Overall survival, disease-specific survival, and progression-free survival

261 related outcomes and 5-year recurrence-free, disease-specific, and overall survival.

262 rom Ang II, in both normal conditions and in disease states, remains only partially understood.

263 s and those with high risk of cardiovascular disease, stroke, heart failure, and atrial fibrillation.

264 Using the Global Burden of Disease study data and methods, we also quantified the b

265 times of MRD assessment, cutoff levels, and disease subtypes.

266 dress established arthropod-borne infectious diseases such as dengue and yellow fever and emerging di

267 For common diseases such as VTE, biobanks provide potential to perf

268 such as dengue and yellow fever and emerging diseases such as Zika and chikungunya, all of which are

269 tect against the development of inflammatory diseases, such as allergy, asthma, and inflammatory bowe

270 f a BAA associated with chronic inflammatory diseases, such as COPD, in patients with hemoptysis, TAE

271 ical for signaling downstream of the Crohn's disease susceptibility protein nucleotide-binding oligom

272 ic variation that plays an important role in disease susceptibility.

273 may reflect underlying cerebral small vessel disease (SVD).

274 velopment and progression of diabetic kidney disease than placebo.

275 anding of the true burden and seasonality of disease that is essential to plan the optimal target gro

276 ment of diverse neurological and psychiatric diseases that are characterized by altered or inappropri

277 me pathogenic mechanisms responsible for the disease, the autoimmune attack on the CNS that leads to

278 In 2 young children with retinal vascular disease, the MIOCTA images showed more detailed vascular

279 population of patients, DCs recruited at the diseased tissue produce high levels of CCL-2 and IL-8 an

280 identify the occurrence of other autoimmune diseases, to control relapses, and to evaluate psychophy

281 ant palliative care involvement early in the disease trajectory.

282 were 17 years old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified with 24

283 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bowel disea

284 e, ulcerative colitis, or inflammatory bowel disease unclassified before the age of 10 years, the dis

285 that the prediction of adult cardiovascular disease using a model comprised entirely of adult nonlab

286 ungunya, all of which are transmitted by the disease vector mosquito Aedes aegypti.

287 AD and CD, and 10 HC with no history of skin disease was analysed using high-throughput proteomic ana

288 Advanced chronic kidney disease was defined by a sustained reduction in eGFR les

289 al response, stable disease, and progressive disease were defined according to the 2014 National Inst

290 Those without prevalent cardiovascular disease were followed until their first CHF event, death

291 ADPKD versus non-ADPKD RRs for biliary tract disease were larger for men than women (heterogeneity P<

292 All-cause death and incident chronic kidney disease were secondary outcomes.

293 l to skin health and can potentially lead to disease when their abundances and activities change due

294 antly protective effect of HLA in autoimmune disease, whereby HLA polymorphism shapes the relative ab

295 d, progression imaging marker of Parkinson's disease, which may be used in clinical trials of disease

296 s revealed major differences between the two diseases, which preferentially involve the PrP(Sc) compo

297 ulin resistance can lead to severe metabolic diseases, while calorie-restricted (CR) diets can improv

298 nhanced laboratory capacity to detect fungal diseases with associated surveillance systems; procureme

299 disease biomarkers, and reposition drugs for diseases with unmet needs.

300 s, ranked among the most prevalent parasitic diseases worldwide.